Global $60+ Billion Blockbuster Oncology Brands Market to 2027 Featuring Bristol Myers Squibb, Merck & Co, Roche, Pfizer, Astrazeneca & Tesaro

DUBLIN /PRNewswire/ -- The "Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brand (Opdivo, Revlimid, Zejula), By Indication (Lung Cancer, Lymphoma, Multiple Myeloma), And Segment Forecasts, 2018 - 2027" report has been added to's offering.

The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, progressing at a CAGR of 7.3% during the forecast period.

Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.

Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo's sales, while Revlimid's patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immuno-therapeutic is expected to trail behind the latter by 2027.

Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.

Further key findings from the report suggest:

  • North America dominated the global arena in 2017, with approximately 65.0% share. The region is likely to maintain its position through 2027
  • In terms of revenue, the lung cancer segment is estimated to expand at a CAGR of over 9.0% during the forecast period
  • The multiple myeloma segment held more than 30.0% of the market revenue in 2017 and is anticipated to lose its position to lung cancer by 2027
  • Europe is projected to experience modest growth during the forecast period due to delays in cost-effectiveness analysis, carried out by health technology assessment bodies, slowing approval process and lowering reimbursement
  • Some of the key companies present in the market are Tesaro, Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.

Key Topics Covered: 

Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Scope And Assumptions
1.3 List Of Abbreviations

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation

Chapter 4 Market Definitions

Chapter 5 Industry Outlook
5.1 Business Segment Trend Analysis
5.2 Pricing Analysis
5.3 Market Variable Analysis
5.3.1 Market Drivers Analysis Accelerated Approvals Expedite Market Launch Immuno-Oncology Therapies As First Line Treatment
5.3.2 Market Restraints Analysis High Therapy Costs Hinders Market Access
5.4 Business Environment Analysis Tools
5.4.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
5.4.2 Porter's Five Forces Analysis

Chapter 6 Competitive & Vendor Lanscape
6.1 Market Participation Categorization
6.1.1 Market Leaders
6.1.2 Innovators
6.2 Strategic Initiatives & Outcome Analysis
6.2.1 List Of Key Strategies, By Company
6.4 List Of Key Companies, By Region
6.5 List Of Key Companies, By Indication
6.6 List Of Key Companies, By Brands
6.7 Company Market Share Analysis

Chapter 7 Regulatory And Political Forces
7.1 Regulatory Landscape
7.1.1 North America
7.1.2 Europe
7.1.3 Asia Pacific
7.1.4 Middle East & Africa
7.1.5 Latin America

Chapter 8 Brands Business Analysis
8.1 Blockbuster Oncology Brands Market: Brand Analysis
8.1.1. Tagrisso
8.1.2 Tecentriq
8.1.3 Ibrance
8.1.4 Perjeta
8.1.5 Zejula
8.1.6 Gazyva
8.1.7 Revlimid
8.1.8 Darzalex
8.1.9 Imbruvica
8.1.10 Opdivo
8.1.11 Keytruda

Chapter 9 Indications Business Analysis
9.1. Blockbuster Oncolgoy Brands: Indications Movement Analysis
9.1.1. Lung Cancer
9.1.2 Breast Cancer
9.1.3 Multiple Myeloma
9.1.4 Lymphoma
9.1.5 Others

Chapter 10 Regional Business Analysis 2015-2027

Chapter 11 Company Profiles

  • Bristol Myers Squibb
  • Merck & Co.
  • Roche
  • Pfizer
  • Astrazeneca
  • Tesaro

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716 


Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Research and Markets

Our purpose is simple - to enable intelligent decision making.

15 years ago we began selling market research reports. Today we are the world's largest market research store - connecting global information professionals with market insights and analysis from 1,700 research teams based across 81 countries.

We are proud to count over 450 of the Fortune 500 as our clients.